4D Molecular Therapeutics (NASDAQ:FDMT) Trading Up 12.8% – Still a Buy?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)’s stock price was up 12.8% on Wednesday . The company traded as high as $9.75 and last traded at $9.78. Approximately 233,290 shares changed hands during mid-day trading, a decline of 69% from the average daily volume of 758,013 shares. The stock had previously closed at $8.67.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, March 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday, April 20th. The Goldman Sachs Group set a $33.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday, May 8th. Chardan Capital restated a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Monday, March 30th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.88.

4D Molecular Therapeutics Price Performance

The company has a market capitalization of $505.02 million, a P/E ratio of -3.76 and a beta of 2.75. The company has a 50 day moving average of $9.43 and a 200-day moving average of $9.13.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. Research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.8 EPS for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

Several large investors have recently added to or reduced their stakes in FDMT. Bank of America Corp DE raised its holdings in 4D Molecular Therapeutics by 17.0% in the 1st quarter. Bank of America Corp DE now owns 974,173 shares of the company’s stock worth $9,070,000 after purchasing an additional 141,582 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of 4D Molecular Therapeutics by 13.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after purchasing an additional 611,276 shares in the last quarter. Exome Asset Management LLC bought a new stake in shares of 4D Molecular Therapeutics during the 1st quarter valued at about $1,216,000. Renaissance Technologies LLC increased its position in shares of 4D Molecular Therapeutics by 12.7% during the first quarter. Renaissance Technologies LLC now owns 578,265 shares of the company’s stock valued at $5,384,000 after buying an additional 65,365 shares during the period. Finally, Sei Investments Co. increased its position in shares of 4D Molecular Therapeutics by 8.9% during the first quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock valued at $120,000 after buying an additional 1,050 shares during the period. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.